ClinicalTrials.gg
CompletedNCT03526679LEADERUpdated Dec 5, 2025Results posted

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

A Phase 1/2 interventional study of Eribulin and Lenvatinib in Leiomyosarcoma, Liposarcoma and Soft Tissue Sarcoma Adult, sponsored by National Taiwan University Hospital. Completed at 2 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by National Taiwan University Hospital · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

This study is designed to test the safety and efficacy of the combination of lenvatinib, a drug that can inhibit the growth of supplying vessels around the tumors, and eribulin, a chemotherapy drug that targets the cancer cell during mitosis, in inoperable or metastatic adipocytic sarcoma and leiomyosarcoma.

Read the detailed description

Recently, the US Food and Drug Administration (FDA) granted approval to eribulin for the treatment of adipocytic sarcoma who have received a prior anthracycline-containing regimen based on a Phase III study results of improved overall survival (OS) as compared with the standard treatment dacarbazine. In the leiomyosarcoma cohort of the study, although eribulin did not demonstrate a significant benefit over dacarbazine, still about 5.1% of leiomyosarcoma patients treated with eribulin had a partial response, suggesting that eribulin may have activity against leiomyosarcoma. However, the overall response rate (ORR) and progression-free survival (PFS) remained unsatisfactory in the two most common soft tissue sarcoma (STS) subtypes-adipocytic sarcoma and leiomyosarcoma, prompting new therapeutic options of STS patients.

Anti-angiogenic therapies had shown promising results in soft tissue sarcoma (ST). Pazopanib, an anti-angiogenic multi-kinase inhibitor, has shown clinical benefit with a longer median PFS of 4.6 months versus placebo in STS patients refractory to at least one line of systemic chemotherapy. Another anti-angiogenic targeted therapy, regorafenib, showed significant improvement in PFS as compared with placebo in various STS. In a phase I study of lenvatinib for solid tumors in Japan, 4 out of 6 leiomyosarcoma patients has tumor decreased more than 10%. Moreover, other tyrosine receptor targets of lenvatinib, such as fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR), may also plays a role in treating STS. In high-grade STS patients, about 30% of patients had FGFR1 amplification or overexpression. FGFR1-overexpression STS cell lines are sensitive to FGFR inhibitors such as BGJ398 and AZD45475. Furthermore, a monoclonal antibody of PDGFR alpha, olaratumab, was recently approved by the FDA in combination with doxorubicin for advanced STS based on a median 10-month OS benefit compared to doxorubicin only in a randomized phase II trial.

It has been demonstrated in various cancer types that an increased quantity of tumor infiltrating lymphocyte (TILs) is associated with increased response to chemotherapy or improved prognosis. One of the factors that had been shown to impede the migration and trafficking of TILs into tumor is vascular endothelial growth factor (VEGF). In renal cell carcinoma, treatment with bevacizumab, an anti-VEGF antibody, or in combination with atezolizumab, increased the recognition of tumor antigen, increased expression of major histocompatibility complex (MHC) class I receptor on tumor cells, and the amount of TIL migration into the tumor stroma9. Many of the STS were detected with scarce TILs in the tumor microenvironment, thus it would be interesting to see if anti-angiogenic tyrosine kinase inhibitors could adjust the tumor microenvironment toward a more chemotherapy-friendly milieu.

Thus, we would like to propose a clinical trial to understand the anti-tumor activity of the combination of lenvatinib and eribulin in advanced STS patients.

02

Conditions studied

  • Leiomyosarcoma
  • Liposarcoma
  • Soft Tissue Sarcoma Adult
  • Advanced Cancer

Keywords

  • soft tissue sarcoma
  • phase Ib/II
  • advanced cancer
03

In context

Leiomyosarcoma

178 studies on the registry are indexed under Leiomyosarcoma; 36 are open to participants now.

This study's enrollment of 30 is below the median of 55 across 152 interventional studies indexed under Leiomyosarcoma.

Browse Leiomyosarcoma studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 578 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A histological confirmed adipocytic sarcoma (dedifferentiated, myxoid, or pleomorphic) or leiomyosarcoma that is either inoperable locally advanced or
  2. Advanced adipocytic sarcoma and leiomyosarcoma who have received no more than 2 in the advanced setting (not including chemotherapy).
  3. At least one measurable tumor according to 1.1. If the has previously received radiotherapy, the tumor must be a progressive lesion after radiotherapy.
  4. PS 0 or 1 or performance status (KPS) ≥ 70
  5. Patients must have adequate organ function and marrow reserve measured within 14 days prior to randomization as defined below:

    • ≥ 9.0 g/dL;
    • ≥ 1,500 /µL;
    • ≥ 75,000/µL;
    • Total ≤ 1.5 x upper normal limit;
    • (AST)/ alanine aminotransferase (ALT) ≤ 2.5 x upper normal limit; for patients with liver metastases AST(SGOT)/ALT(SGPT) ≤ 5 x upper normal limit is allowed;
    • Serum creatinine ≤ 1.5mg/dL or ≥ 50ml/min;
    • (aPTT) \< 1.5 x upper normal limit (unless on therapeutic anti-coagulation);
    • Proteinuria ≤ 1+ with urine dipstick, if > 1+, 24-hour urine protein must be ≤ 1 g
  6. Age 20 or older.
  7. Patient's is more than 3 months
  8. All women of must have a negative pregnancy test obtained within 72 hours before starting therapy.
  9. Patients with must use effective (hormone or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after the completion of therapy.
  10. Patient needs to have adequate from previous systemic treatment(s):

(1) 2 weeks for any other oral anti-cancer targeted agents (2) 3 weeks for any other cytotoxic chemotherapy (except for mitomycin-C, which will require 6 weeks) (3) 3 weeks for monoclonal antibodies, including

Exclusion criteria

Exclusion criteria

  1. Patients who had received lenvatinib or eribulin treatment
  2. Patients who had , either diagnosed by brain imaging study or confirmed by cerebrospinal fluid cytology examination (patients with that are under control is eligible).
  3. Patients with clinical signs or symptoms of gastrointestinal obstruction and who require parenteral hydration and/or nutrition because of obstruction.
  4. Patients with uncontrollable hypertension (defined as systolic blood pressure over 140mmHg and/or diastolic pressure over 90mmHg despite anti-hypertensive medications)
  5. Patients with the following cardiac disease

    • Prolongation of (QTc) interval to >480 milliseconds (ms).
    • Significant cardiovascular impairment: history of (a) congestive heart failure greater than (NYHA) Class II; (b) unstable angina; (c) myocardial infarction; (d) stroke; or (e) cardiac arrhythmia associated with hemodynamic instability within 6 months of the first dose of study drugs.
  6. Bleeding subjects at risk for severe hemorrhage.
  7. Arterial thromboembolic event within the past 6 months, including , cerebrovascular accident, unstable angina, or myocardial infarction.
  8. Major surgical procedure, open , or significant traumatic injury within 28 days prior to enrollment.
  9. History of allergic reaction to compounds of similar chemical composition to the study drugs
  10. Pregnancy or lactation.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Experimental arm

    The combination of lenvatinib and eribulin

    Drug: Eribulin · Drug: Lenvatinib

Interventions

  • lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days

    Also known as: Halaven

  • lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days

    Also known as: Lenvima

06

What researchers measure

Primary outcomes

  1. The Objective Response Rate (ORR) Based on RECIST 1.1

    We will measure the radiographic changes of the tumor based on a prespecified criteria called RECIST (Response evaluation criteria in solid tumors). A tumor decreased in the sum of longest diameters of measurable tumors of more than 30% is considered responsive; a growth of tumor more than 20% in the sum of the longest diameter is considered disease progression; and shrinkage or growth between these intervals is considered stable disease (SD).

    Time frame: 24 weeks

Secondary outcomes

  1. The Proportion of Patients Who Are Progression-free and Alive at 24 Weeks

    We will measure how many patients (proportion) of the participants that the tumor has progressed in the first 24 weeks of treatment

    Time frame: 24 weeks

  2. Overall Survival (OS) Rate at 12-months

    The definition of 12-months OS rate is the percentage of patients who had NOT has an event before or at 12 months. An event is defined as follows: Death due to any cause.

    Time frame: 12 months

  3. Overall Survival (OS) Rate at 6 Months

    The definition of 6 months OS rate is the percentage of patients who had NOT has an event before or at 6 months. An event is defined as follows: Death due to any cause.

    Time frame: 6 months

  4. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Toxicities will be assessed according to CTCAE 4.03. The number of all grade toxicities will be recorded

    Time frame: 6 months

07

Results

Posted Nov 25, 2024

Participant flow

Participant flow — Overall Study
MilestoneExperimental arm
Started30
Completed28
Not completed2
Withdrew: Still under treatment2

Outcome measures

PrimaryThe Objective Response Rate (ORR) Based on RECIST 1.1

We will measure the radiographic changes of the tumor based on a prespecified criteria called RECIST (Response evaluation criteria in solid tumors). A tumor decreased in the sum of longest diameters of measurable tumors of more than 30% is considered responsive; a growth of tumor more than 20% in the sum of the longest diameter is considered disease progression; and shrinkage or growth between these intervals is considered stable disease (SD).

Time frame:
24 weeks
Reported as:
Count of participants · Participants
The Objective Response Rate (ORR) Based on RECIST 1.1
ParticipantsExperimental arm
The Objective Response Rate (ORR) Based on RECIST 1.16
SecondaryThe Proportion of Patients Who Are Progression-free and Alive at 24 Weeks

We will measure how many patients (proportion) of the participants that the tumor has progressed in the first 24 weeks of treatment

Time frame:
24 weeks
Reported as:
Count of participants · Participants
The Proportion of Patients Who Are Progression-free and Alive at 24 Weeks
ParticipantsExperimental arm
The Proportion of Patients Who Are Progression-free and Alive at 24 Weeks30
SecondaryOverall Survival (OS) Rate at 12-months

The definition of 12-months OS rate is the percentage of patients who had NOT has an event before or at 12 months. An event is defined as follows: Death due to any cause.

Time frame:
12 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS) Rate at 6 Months

The definition of 6 months OS rate is the percentage of patients who had NOT has an event before or at 6 months. An event is defined as follows: Death due to any cause.

Time frame:
6 months

Results for this outcome have not been posted.

SecondaryIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Toxicities will be assessed according to CTCAE 4.03. The number of all grade toxicities will be recorded

Time frame:
6 months

Results for this outcome have not been posted.

Adverse events

Collected over 1 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental arm12/30 (40%)20/30 (66.7%)22/30 (73.3%)
Most frequent serious events
Most frequent serious events
EventExperimental arm
neutrophil decreaseBlood and lymphatic system disorders11/30
Hand-foot syndromeSkin and subcutaneous tissue disorders5/30
HypertensionVascular disorders4/30
Most frequent other events
Most frequent other events
EventExperimental arm
Hand-foot syndromeSkin and subcutaneous tissue disorders22/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Experimental Arm
<=18 years0
Between 18 and 65 years25
>=65 years5
Age, Continuous
Age, Continuous(years)Experimental Arm
Median59 (29 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)Experimental Arm
Female20
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental Arm
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported30
Region of Enrollment
Region of Enrollment(participants)Experimental Arm
Taiwan30
08

Study locations

2 sites
  • Taipei Veterans General Hospital
    Taipei, Taiwan, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
09

References and documents

Publications

  • Chen TW, Hsu CL, Hong RL, Lee JC, Chang K, Yu CW, Chen SC, Guo JC, Chen ML, Hsu MC, Kung TF, Cheng AL, Yen CC. A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma. Clin Cancer Res. 2022 Dec 1;28(23):5058-5065. doi: 10.1158/1078-0432.CCR-22-2092. PubMed 36129471 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Jun 2021, 35 months.

Results were first posted in Nov 2024, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2018
First posted
May 16, 2018
StartActual
Jul 12, 2018
Primary completionActual
Jun 30, 2021
CompletionActual
Oct 30, 2025
Results first posted
Nov 25, 2024
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03526679
Responsible party
Sponsor
First posted
May 16, 2018
Start date
Jul 12, 2018
Primary completion
Jun 30, 2021
Completion
Oct 30, 2025
Results posted
Nov 25, 2024
Last update
Dec 5, 2025

Study contacts

Wei-Wu Chen, MD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eribulin · Lenvatinib

Start the discussion